top selling glp-1 drugs Pharma's Top-Selling in Q1 2025: Oncology, Immunology, and | Pharmint posted on the topic GLP-1 Receptor Agonist Shortage: Challenges
Description
[48] Pancreatic and thyroid safety [edit] Historically, GLP-1 receptor agonists have carried warnings regarding acute pancreatitis and pancreatic cancer
J.TzvetkovM
Report Building a long-range GLP-1 forecast: When could commercial health plans see a plateau
The least-squares mean percentage change in body weight at 24 weeks in the retatrutide groups was 7.2% in the 1 mg group, and up to 17.5% in the 12 mg group, as compared with 1.6% in the placebo group
